CRT Capital upgraded shares of Tenet Healthcare (NYSE: THC) from a fair value rating to a buy rating in a research note released on Friday morning. They currently have $51.00 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Tenet Healthcare from $20.00 to $38.00 in a research note to investors on Thursday, March 7th. They now have a sector perform rating on the stock. Separately, analysts at Jefferies Group reiterated a buy rating on shares of Tenet Healthcare in a research note to investors on Monday, March 4th. They now have a $48.00 price target on the stock, up previously from $26.00. Finally, analysts at JPMorgan Chase reiterated an overweight rating on shares of Tenet Healthcare in a research note to investors on Monday, March 4th. They now have a $41.00 price target on the stock.
Shares of Tenet Healthcare traded up 1.50% during mid-day trading on Friday, hitting $43.85. Tenet Healthcare has a one year low of $17.24 and a one year high of $43.79. The stock’s 50-day moving average is currently $39.42. The company has a market cap of $4.573 billion and a P/E ratio of 33.33.
Tenet Healthcare Corporation, and its subsidiaries (Tenet) is an investor-owned health care services company whose subsidiaries and affiliates own and operate acute care hospitals, ambulatory surgery centers, diagnostic imaging centers and related health care facilities.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
